Miho Kazui

Summary

Affiliation: Daiichi Sankyo Co
Country: Japan

Publications

  1. doi Human Intestinal Raf Kinase Inhibitor Protein (RKIP) Catalyzes Prasugrel as a Bioactivation Hydrolase
    Miho Kazui
    Drug Metabolism and Pharmacokinetics Research Laboratories, Daiichi Sankyo Co, Ltd M K, K H, A K, and Daiichi Sankyo RD Novare Co, Ltd Y O, K K, Tokyo, Japan
    Drug Metab Dispos 44:115-23. 2016
  2. doi Hepatic microsomal thiol methyltransferase is involved in stereoselective methylation of pharmacologically active metabolite of prasugrel
    Miho Kazui
    Drug Metabolism and Pharmacokinetics Research Laboratories, Daiichi Sankyo Co, Ltd, Tokyo M K, K H, T Iz, A K Yokohama College of Pharmacy, Yokohama T Ik, Japan
    Drug Metab Dispos 42:1138-45. 2014
  3. doi Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite
    Miho Kazui
    Drug Metabolism and Pharmacokinetics Research Laboratories, Daiichi Sankyo Co, Ltd, 1 2 58 Hiromachi, Shinagawa ku, Tokyo, 140 8710, Japan
    Drug Metab Dispos 38:92-9. 2010
  4. doi A possible mechanism for the differences in efficiency and variability of active metabolite formation from thienopyridine antiplatelet agents, prasugrel and clopidogrel
    Katsunobu Hagihara
    Drug Metabolism and Pharmacokinetics Research Laboratories, Daiichi Sankyo Co, Ltd, 1 2 58 Hiromachi, Shinagawa ku, Tokyo, 140 8710, Japan
    Drug Metab Dispos 37:2145-52. 2009
  5. doi Glutaredoxin is involved in the formation of the pharmacologically active metabolite of clopidogrel from its GSH conjugate
    Katsunobu Hagihara
    Drug Metabolism and Pharmacokinetics Research Laboratories, Daiichi Sankyo Co, Ltd, 1 2 58 Hiromachi, Shinagawa ku, Tokyo 140 8710, Japan
    Drug Metab Dispos 40:1854-9. 2012
  6. doi Biotransformation of prasugrel, a novel thienopyridine antiplatelet agent, to the pharmacologically active metabolite
    Katsunobu Hagihara
    Daiichi Sankyo Co, Ltd, 1 2 58 Hiromachi, Shinagawa ku, Tokyo, 140 8710, Japan
    Drug Metab Dispos 38:898-904. 2010
  7. doi Glutaredoxin and thioredoxin can be involved in producing the pharmacologically active metabolite of a thienopyridine antiplatelet agent, prasugrel
    Katsunobu Hagihara
    Drug Metabolism and Pharmacokinetics Research Laboratories, Daiichi Sankyo Co, Ltd, 1 2 58 Hiromachi, Shinagawa ku, Tokyo, 140 8710, Japan
    Drug Metab Dispos 39:208-14. 2011
  8. doi The intestine as an important contributor to prasugrel active metabolite formation in vivo
    Katsunobu Hagihara
    Drug Metabolism and Pharmacokinetics Research Laboratories, Daiichi Sankyo Co, Ltd, 1 2 58 Hiromachi, Shinagawa ku, Tokyo, Japan
    Drug Metab Dispos 39:565-70. 2011
  9. ncbi Comparison of human cytochrome P450 inhibition by the thienopyridines prasugrel, clopidogrel, and ticlopidine
    Katsunobu Hagihara
    Drug Metabolism and Pharmacokinetics Research Laboratories, Daiichi Sankyo Co, Ltd, Japan
    Drug Metab Pharmacokinet 23:412-20. 2008
  10. doi Absorption, distribution, metabolism and excretion of loxoprofen after dermal application of loxoprofen gel to rats
    Ryoko Sawamura
    Drug Metabolism and Pharmacokinetics Research Laboratories, Daiichi Sankyo Co, Ltd, Hiromachi, Shinagawa ku, Tokyo, Japan
    Xenobiotica 44:1026-38. 2014

Detail Information

Publications10

  1. doi Human Intestinal Raf Kinase Inhibitor Protein (RKIP) Catalyzes Prasugrel as a Bioactivation Hydrolase
    Miho Kazui
    Drug Metabolism and Pharmacokinetics Research Laboratories, Daiichi Sankyo Co, Ltd M K, K H, A K, and Daiichi Sankyo RD Novare Co, Ltd Y O, K K, Tokyo, Japan
    Drug Metab Dispos 44:115-23. 2016
    ..RKIP is known to have diverse functions in many intracellular signaling cascades, but this is the first report describing RKIP as a hydrolase involved in drug metabolism. ..
  2. doi Hepatic microsomal thiol methyltransferase is involved in stereoselective methylation of pharmacologically active metabolite of prasugrel
    Miho Kazui
    Drug Metabolism and Pharmacokinetics Research Laboratories, Daiichi Sankyo Co, Ltd, Tokyo M K, K H, T Iz, A K Yokohama College of Pharmacy, Yokohama T Ik, Japan
    Drug Metab Dispos 42:1138-45. 2014
    ....
  3. doi Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite
    Miho Kazui
    Drug Metabolism and Pharmacokinetics Research Laboratories, Daiichi Sankyo Co, Ltd, 1 2 58 Hiromachi, Shinagawa ku, Tokyo, 140 8710, Japan
    Drug Metab Dispos 38:92-9. 2010
    ..These results help explain the role of genetic polymorphism of CYP2C19 and also the effect of potent CYP3A inhibitors on the pharmacokinetics and pharmacodynamics of clopidogrel in humans and on clinical outcomes...
  4. doi A possible mechanism for the differences in efficiency and variability of active metabolite formation from thienopyridine antiplatelet agents, prasugrel and clopidogrel
    Katsunobu Hagihara
    Drug Metabolism and Pharmacokinetics Research Laboratories, Daiichi Sankyo Co, Ltd, 1 2 58 Hiromachi, Shinagawa ku, Tokyo, 140 8710, Japan
    Drug Metab Dispos 37:2145-52. 2009
    ....
  5. doi Glutaredoxin is involved in the formation of the pharmacologically active metabolite of clopidogrel from its GSH conjugate
    Katsunobu Hagihara
    Drug Metabolism and Pharmacokinetics Research Laboratories, Daiichi Sankyo Co, Ltd, 1 2 58 Hiromachi, Shinagawa ku, Tokyo 140 8710, Japan
    Drug Metab Dispos 40:1854-9. 2012
    ..9 ± 7.5 μl · min⁻¹ · μg⁻¹. In conclusion, we found that human glutaredoxin is a main contributor to the formation of the pharmacologically active metabolite of clopidogrel from its GSH conjugate in human liver...
  6. doi Biotransformation of prasugrel, a novel thienopyridine antiplatelet agent, to the pharmacologically active metabolite
    Katsunobu Hagihara
    Daiichi Sankyo Co, Ltd, 1 2 58 Hiromachi, Shinagawa ku, Tokyo, 140 8710, Japan
    Drug Metab Dispos 38:898-904. 2010
    ....
  7. doi Glutaredoxin and thioredoxin can be involved in producing the pharmacologically active metabolite of a thienopyridine antiplatelet agent, prasugrel
    Katsunobu Hagihara
    Drug Metabolism and Pharmacokinetics Research Laboratories, Daiichi Sankyo Co, Ltd, 1 2 58 Hiromachi, Shinagawa ku, Tokyo, 140 8710, Japan
    Drug Metab Dispos 39:208-14. 2011
    ..This study is the first in vitro observation indicating that glutaredoxin and thioredoxin in human liver are active in reducing the mixed disulfide formed between xenobiotics and glutathione...
  8. doi The intestine as an important contributor to prasugrel active metabolite formation in vivo
    Katsunobu Hagihara
    Drug Metabolism and Pharmacokinetics Research Laboratories, Daiichi Sankyo Co, Ltd, 1 2 58 Hiromachi, Shinagawa ku, Tokyo, Japan
    Drug Metab Dispos 39:565-70. 2011
    ..In conclusion, this is the first report to directly demonstrate that the conversion of prasugrel to R-138727 in the intestine is comparable to that converted in the liver of dogs...
  9. ncbi Comparison of human cytochrome P450 inhibition by the thienopyridines prasugrel, clopidogrel, and ticlopidine
    Katsunobu Hagihara
    Drug Metabolism and Pharmacokinetics Research Laboratories, Daiichi Sankyo Co, Ltd, Japan
    Drug Metab Pharmacokinet 23:412-20. 2008
    ..The active metabolites of clopidogrel and prasugrel and clopidogrel acid metabolite also did not affect the activities of the P450s examined...
  10. doi Absorption, distribution, metabolism and excretion of loxoprofen after dermal application of loxoprofen gel to rats
    Ryoko Sawamura
    Drug Metabolism and Pharmacokinetics Research Laboratories, Daiichi Sankyo Co, Ltd, Hiromachi, Shinagawa ku, Tokyo, Japan
    Xenobiotica 44:1026-38. 2014
    ..The radioactivity revealed similar metabolite profiles in both administration routes...